Citius Oncology, Inc. (CTOR) stock

CTORNasdaqPharmaceutical PreparationsFiscal year ends September 30

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30

$0.52−0.03 (-5.87%)

Close on Nov 12, 2026Market cap $48.56MP/E –Yield –

Citius Oncology ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Citius Oncology has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?